Clinical efficacy of intra-articular parecoxib injection for the treatment of early knee osteoarthritis

Abstract

To observe and evaluate the clinical effect of intra-articular injection of parecoxib in patients with early knee osteoarthritis. From September 2016 to August 2017, 107 patients with early knee osteoarthritis were treated, including 50 males and 57 females, aged 45 to 64 (51.9±4.2) years. They were divided into basic therapy+oral glucosamine group(group A) 36 cases, oral celecoxib+basic therapy+oral glucosamine group(group B) 36 cases, intra-articular injection of parecoxib+basic therapy+oral glucosamine group(group C) 35 cases. There was no significant difference in gender, age, BMI and clinical stage(Kellgren-Lawrence classification) between the three groups before treatment. VAS score, HSS score and patient satisfaction were compared before and after treatment in the three groups. The levels of inflammatory cytokines in synovial fluid were measured before and after treatment in the three groups. All cases were followed up for(15.2±2.6) months on average. The VAS score and HSS score of each group were improved after treatment(P<0.001). There were significant differences in VAS and HSS scores among the three groups after treatment(P<0.001). The clinical efficacy of group C was better than that of group A and B(P<0.001), group B was better than that of group A(P<0.001), and group C had the highest satisfaction(P<0.001). After treatment, the concentration of proinflammatory factor TNF-α and IL-6 in the synovial fluid of each group decreased(P<0.001) and the concentration of anti-inflammatory factor IL-10 increased(P<0.001). After treatment, the concentrations of TNF-α, IL-6 and IL-10 in the synovial fluid of the three groups were significantly different(P<0.001). For patients with early knee osteoarthritis, intra-articular injection of parecoxib can significantly improve clinical symptoms and avoid adverse reactions of long-term oral NSAIDs, which is an effective treatment.